| __timestamp | Halozyme Therapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 49315000 |
| Thursday, January 1, 2015 | 40028000 | 75043000 |
| Friday, January 1, 2016 | 45853000 | 83749000 |
| Sunday, January 1, 2017 | 53816000 | 122682000 |
| Monday, January 1, 2018 | 60804000 | 207761000 |
| Tuesday, January 1, 2019 | 77252000 | 284812000 |
| Wednesday, January 1, 2020 | 45736000 | 317875000 |
| Friday, January 1, 2021 | 50323000 | 282660000 |
| Saturday, January 1, 2022 | 143526000 | 451421000 |
| Sunday, January 1, 2023 | 149182000 | 481871000 |
| Monday, January 1, 2024 | 154335000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Halozyme Therapeutics, Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Halozyme's SG&A expenses grew by approximately 315%, while Sarepta's surged by nearly 878%. Despite this, Halozyme's average annual SG&A expenses were about 70% lower than Sarepta's, indicating a more controlled cost structure. Notably, in 2022, Halozyme's expenses spiked by 184% compared to the previous year, reflecting strategic investments or operational shifts. Meanwhile, Sarepta's consistent upward trend suggests aggressive expansion or increased operational complexity. Understanding these dynamics offers valuable insights into each company's strategic priorities and financial health.
Johnson & Johnson or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Johnson & Johnson and Halozyme Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Sarepta Therapeutics, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Halozyme Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Ascendis Pharma A/S
Sarepta Therapeutics, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Lantheus Holdings, Inc.
Operational Costs Compared: SG&A Analysis of Sarepta Therapeutics, Inc. and ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Halozyme Therapeutics, Inc. and Novavax, Inc.